Disclosed herein are stents for implantation within the body and methods for delivery and/or deployment. Certain embodiments disclosed herein may be used in procedures to treat May-Thurner syndrome and/or deep venous thrombosis and the resulting post-thrombotic syndrome.
May-Thurner syndrome, also known as iliac vein compression syndrome, is a condition in which compression of the common venous outflow tract of the left lower extremity may cause various adverse effects, including, but not limited to, discomfort, swelling, pain, and/or deep venous thrombosis (DVT) (commonly known as blood clots). May-Thurner syndrome occurs when the left common iliac vein is compressed by the overlying right common iliac artery, leading to stasis of blood, which may cause the formation of blood clots in some individuals. Other, less common, variations of May-Thurner syndrome have been described, such as compression of the right common iliac vein by the right common iliac artery.
While May-Thurner syndrome is thought to represent between two to five percent of lower-extremity venous disorders, it frequently goes unrecognized. Nevertheless, it is generally accepted that May-Thurner syndrome is about three times more common in women than it is in men and typically manifests itself between the age of twenty and forty. Patients exhibiting both hypercoagulability and left lower extremity thrombosis may be suffering from May-Thurner syndrome. To confirm that diagnosis, it may be necessary to rule out other causes for hypercoagulable state, for example by evaluating levels of antithrombin, protein C, protein S, factor V Leiden, and prothrombin G20210A.
By contrast to the right common iliac vein, which ascends almost vertically parallel to the inferior vena cava, the left common iliac vein takes a more transverse course. Along this course, it lies under the right common iliac artery, which may compress it against the lumbar spine. Iliac vein compression is a frequent anatomic variant—it is thought that as much as 50% luminal compression of the left iliac vein occurs in a quarter of healthy individuals. However, compression of the left common iliac vein becomes clinically significant only if such compression causes appreciable hemodynamic changes in venous flow or venous pressure, or if it leads to acute or chronic deep venous thrombosis, which will be discussed in more detail below. In addition to the other problems associated with compression, the vein may also develop intraluminal fibrous spurs from the effects of the chronic pulsatile compressive force from the overlying artery.
The narrowed, turbulent channel associated with May-Thurner syndrome may predispose the afflicted patient to thrombosis. And, the compromised blood flow often causes collateral blood vessels to form—most often horizontal transpelvis collaterals, connecting both internal iliac veins to create additional outflow possibilities through the right common iliac vein. Sometimes vertical collaterals are formed, most often paralumbar, which can cause neurological symptoms, like tingling and numbness.
Current best practices for the treatment and/or management of May-Thurner syndrome is proportional to the severity of the clinical presentation. Leg swelling and pain is best evaluated by vascular specialists, such as vascular surgeons, interventional cardiologists, and interventional radiologists, who both diagnose and treat arterial and venous diseases to ensure that the cause of the extremity pain is evaluated. Diagnosis of May-Thurner syndrome is generally confirmed one or more imaging modalities that may include magnetic resonance venography, and venogram, which, because the collapsed/flattened left common iliac may not be visible or noticed using conventional venography, are usually confirmed with intravascular ultrasound. To prevent prolonged swelling or pain as downstream consequences of the left common iliac hemostasis, blood flow out of the leg should be improved/increased. Early-stage or uncomplicated cases may be managed simply with compression stockings. Late-stage or severe May-Thurner syndrome may require thrombolysis if there is a recent onset of thrombosis, followed by angioplasty and stenting of the iliac vein after confirming the diagnosis with a venogram or an intravascular ultrasound. A stent may be used to support the area from further compression following angioplasty. However, currently available stenting options suffer from several complications—including severe foreshortenting, lack of flexibility (which can force the vessel to straighten excessively), vessel wear and eventual perforation, increased load on and deformation of the stent causing early fatigue failure, and/or impedance of flow in the overlying left iliac artery potentially causing peripheral arterial disease. The compressed, narrowed outflow channel present in May-Thurner syndrome may cause stasis of the blood, which an important contributing factor to deep vein thrombosis.
Some patients suffering from May-Thurner syndrome may exhibit thrombosis while others may not. Nevertheless, those patients that do not experience thrombotic symptoms may still experience thrombosis at any time. If a patient has extensive thrombosis, pharmacologic and/or mechanical (i.e., pharmacomechanical) thrombectomy may be necessary. The hemostasis caused by May-Thurner syndrome has been positively linked to an increased incidence of deep vein thrombosis (“DVT”).
Deep vein thrombosis, or deep venous thrombosis, is the formation of a blood clot (thrombus) within a deep vein, predominantly in the legs. The right and left common iliac are common locations for deep vein thrombosis, but other locations of occurrence are common. Non-specific symptoms associated with the condition may include pain, swelling, redness, warmness, and engorged superficial veins. Pulmonary embolism, a potentially life-threatening complication of deep vein thrombosis, is caused by the detachment of a partial or complete thrombus that travels to the lungs. Post-thrombotic syndrome, another long-term complication associated with deep venous thrombosis, is a medical condition caused by a reduction in the return of venous blood to the heart and can include the symptoms of chronic leg pain, swelling, redness, and ulcers or sores.
Deep vein thrombosis formation typically begins inside the valves of the calf veins, where the blood is relatively oxygen deprived, which activates certain biochemical pathways. Several medical conditions increase the risk for deep vein thrombosis, including cancer, trauma, and antiphospholipid syndrome. Other risk factors include older age, surgery, immobilization (e.g., as experienced with bed rest, orthopedic casts, and sitting on long flights), combined oral contraceptives, pregnancy, the postnatal period, and genetic factors. Those genetic factors include deficiencies with antithrombin, protein C, and protein S, the mutation of Factor V Leiden, and the property of having a non-O blood type. The rate of new cases of deep vein thrombosis increases dramatically from childhood to old age; in adulthood, about 1 in 1000 adults develops the condition annually.
Common symptoms of deep vein thrombosis include pain or tenderness, swelling, warmth, redness or discoloration, and distention of surface veins, although about half of those with the condition have no symptoms. Signs and symptoms alone are not sufficiently sensitive or specific to make a diagnosis, but when considered in conjunction with known risk factors can help determine the likelihood of deep vein thrombosis. Deep vein thrombosis is frequently ruled out as a diagnosis after patient evaluation: the suspected symptoms are more often due to other, unrelated causes, such as cellulitis, Baker's cyst, musculoskeletal injury, or lymphedema. Other differential diagnoses include hematoma, tumors, venous or arterial aneurysms, and connective tissue disorders.
Anticoagulation, which prevents further coagulation but does not act directly on existing clots, is the standard treatment for deep vein thrombosis. Other, potentially adjunct, therapies/treatments may include compression stockings, selective movement and/or stretching, inferior vena cava filters, thrombolysis, and thrombectomy.
In any case, treatment of various venous maladies, including those described above, can be improved with stents. Improvements in stents for venous use are therefore desired.
Accordingly, the present invention in accordance with various embodiments is directed to an implantable intravascular stent for deployment that obviates one or more of the problems due to limitations and disadvantages of the related art.
Disclosed herein are expandable stents that include pluralities of main struts and connector struts. The inventors have designed the struts of and flexible connectors with structure, including areas of expanded or reduced width or thickness, to account for venous applications. As another example, the inventors have recognized that venous applications benefit from configurations that improve flexibility (due to the greater elasticity of venous applications) while maintaining enough stiffness to resist pressure on the venous structure in selected areas (such as for the May-Thurner syndrome).
Stent embodiments below address the above-described needs and confer other advantages by providing a stent structure that reduces foreshortening while providing radial stiffness and flexibility particularly well suited for venous (and similar) applications. Such improvements are, for example, provided by use of oblique (or helically) oriented stent struts with opposingly oriented oblique connectors that form strips or strip fragments. Those strips or strip fragments (or portions) are then interconnected with flexible connectors that further reduce/minimize shortening.
In one embodiment, a stent includes at least one strip including a plurality of main struts and a plurality of first connector struts. The main struts are obliquely oriented to a longitudinal axis of the stent and extend circumferentially around the longitudinal axis of the stent. The first connector struts extend between and connect circumferentially adjacent pairs of the main struts. The stent also includes a plurality of second connector struts extending between and connecting adjacent strip portions. Ends of the second connector struts are connected to the main struts between ends of the main struts so as to reduce foreshortening of the stent during expansion.
In one aspect, the at least one strip is formed into a generally tubular structure. In another aspect, the ends of the main struts define edges of the at least one strip. In another aspect, the main struts are generally straight. In another aspect, the main struts have a width that is at least twice the width of the first connector struts. In another aspect, the main struts of the at least one strip are each oriented at the same oblique angle to the longitudinal axis of the stent.
In another aspect, the main struts of the at least one strip are each oriented at the same oblique angle to the longitudinal axis of the stent and the oblique angle is between 10 to 50 degrees from the longitudinal axis of the stent. In another aspect, the main struts are longer than the first connector struts. In another aspect, the length of each first connector strut is 30%, 50%, or 70% of the length of each main strut.
In another aspect, at least a pair of first connector struts connects each pair of the main struts. In another aspect, an end of one of the pair of first connector struts is connected to an end of one of the pair of the main struts. In another aspect, an end of the second one of the pair of the first connector struts is connected to the opposite end of the other of the pair of main struts.
In another aspect, the first connector struts are obliquely oriented to the longitudinal axis of the stent. In another aspect, the first connector struts are all oriented at the same oblique angle to the longitudinal axis of the stent. In another aspect, the first connector struts are oriented generally opposite the main struts.
In another aspect, each of the first connector struts is generally straight between its ends. In another aspect, the ends of the second connector struts are attached to a middle portion of the main struts. In another aspect, each of the second connector struts has at least one bend. In another aspect, each of the second connector struts has two bends curving in generally opposite directions. In another aspect, the second connector struts attach to a side of the main struts opposite another side of the main struts to which the first connector struts are attached.
In another embodiment, a stent includes at least one strip extending helically around a longitudinal axis of the stent. The at least one strip includes a plurality of main struts and a plurality of first connector struts. The main struts are obliquely oriented to a longitudinal axis of the stent and extend helically around the longitudinal axis of the stent, and the first connector struts extend between and connect circumferentially adjacent pairs of the main struts. The stent also includes a plurality of second connector struts extending between and connecting adjacent strip portions. Ends of the second connector struts are connected to the main struts between ends of the main struts so as to reduce foreshortening of the stent during expansion.
In one aspect, the second connector struts connect adjacent main struts between a middle portion of one main strut to the middle portion of a respective adjacent main strut. In another aspect, each of the second connector struts has at least one bend. In another aspect, each of the second connector struts has at least two bends curving in generally opposite directions.
In another aspect, the first connector struts are obliquely oriented to the longitudinal axis of the stent. In another aspect, the first connector struts are obliquely oriented to the longitudinal axis in a direction that is generally opposite the oblique orientation of the main struts. In another aspect, the main struts are generally straight. In another aspect, the main struts have a width that is at least twice the width of the first connector struts.
In another aspect, the main struts of the at least one strip are each oriented at the same oblique angle to the longitudinal axis of the stent. In another aspect, the main struts of the at least one strip are each oriented at the same oblique angle to the longitudinal axis of the stent and the oblique angle is between 10 to 50 degrees from the longitudinal axis of the stent. In another aspect, the main struts are longer than the first connector struts. In another aspect, the length of each first connector strut is 30%, 50%, or 70% of the length of each main strut.
In another aspect, at least a pair of first connector struts connects each pair of the main struts. In another aspect, an end of one of the pair of first connector struts is connected to an end of one of the pair of the main struts. In another aspect, an end of another one of the pair of the first connector struts is connected to an end of another one of the pair of main struts. In another aspect, each of the first connector struts is generally straight between its ends.
In another embodiment, a stent includes at least two strips including a plurality of main struts and a plurality of first connector struts. The main struts are obliquely oriented to a longitudinal axis of the stent and extend circumferentially around the longitudinal axis of the stent. The first connector struts extend between and connect circumferentially adjacent pairs of the main struts, and the at least two strips form at least two respective circumferential rings. The stent also includes a plurality of second connector struts extending between and connecting adjacent circumferential rings. Ends of the second connector struts are connected to the main struts between ends of the main struts so as to reduce foreshortening of the stent during expansion.
In one aspect, the at least two circumferential rings extend serially along the longitudinal axis of the stent. In another aspect, each respective main strut has an oblique orientation to the longitudinal axis of the stent that is generally opposite the oblique orientation of a respective main strut of an adjacent strip. In another aspect, the first connector struts of each of the at least two strips have an oblique orientation to the longitudinal axis of the stent that is generally opposite the oblique orientation of the first connector struts of an adjacent strip of the at least two strips.
In another aspect, the ends of the main struts define edges of each of the at least two strips. In another aspect, the main struts are generally straight. In another aspect, the main struts have a width that is at least twice the width of the first connector struts. In another aspect, the main struts of the at least two strips are each oriented at the same oblique angle to the longitudinal axis of the stent. In another aspect, the main struts of the at least two strips are each oriented at the same oblique angle to the longitudinal axis of the stent and the oblique angle is between 10 to 50 degrees from the longitudinal axis of the stent.
In another aspect, the main struts are longer than the first connector struts. In another aspect, the length of each first connector strut is 30%, 50%, or 70% of the length of each main strut. In another aspect, at least a pair of first connector struts connects each pair of the main struts. In another aspect, an end of one of the pair of first connector struts is connected to an end of one of the pair of the main struts. In another aspect, an end of another one of the pair of the first connector struts is connected to an end of another one of the pair of main struts.
In another aspect, the first connector struts are obliquely oriented to the longitudinal axis of the stent. In another aspect, the first connector struts of each strip are all oriented at the same oblique angle to the longitudinal axis of the stent. In another aspect, the first connector struts are oriented generally opposite the main struts.
In another aspect, each of the first connector struts is generally straight between its ends. In another aspect, the ends of the second connector struts are attached to a middle portion of the main struts. In another aspect, the second connector struts have an arc shape extending over a space between adjacent circumferential rings.
Further embodiments, features, and advantages of the intravascular stent, as well as the structure and operation of the various embodiments of the intravascular stent, are described in detail below with reference to the accompanying drawings.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.
The accompanying figures, which are incorporated herein and form part of the specification, illustrate an intravascular stent. Together with the description, the figures further serve to explain the principles of the intravascular stent described herein and thereby enable a person skilled in the pertinent art to make and use the intravascular stent.
The inventors have observed certain problems in the prior art associated with foreshortening of stents, and in particular foreshortening of stents used for venous applications. Foreshortening causes difficulty in accurately placing the stent in the patient's lumen, since the end which exits the delivery system first will either move the lumen or move in the lumen, toward the constrained end during the deployment. Additionally, this movement can cause trauma to the already compromised/fragile lumen being treated.
Accurate placement is ideal in all medical interventions, but it is vital in areas where the end that is first deployed is critical. Such areas include at vessel bifurcations and branch vessels, so that the implant does not enter or interfere with the portion of the vessel that does not require treatment. Such a bifurcation is present at the inferior vena cava where it branches into right and left iliac veins, as described in more detail below.
May-Thurner syndrome, or iliac vein compression syndrome, occurs in the peripheral venous system when the iliac artery compresses the iliac vein against the spine as shown in
As shown, the strong right common iliac artery has compressed the iliac vein causing it to become narrowed. This is one possible, if not a classic, manifestation of May-Thurner syndrome. Over time, such narrowing may cause vascular scarring which can result in intraluminal changes that could precipitate iliofemoral venous outflow obstruction and/or deep vein thrombosis. As discussed above, venous insufficiency (i.e., a condition in which the flow of blood through the veins is impaired) can ultimately lead to various deleterious pathologies including, but not limited to, pain, swelling, edema, skin changes, and ulcerations. Venous insufficiency is typically brought on by venous hypertension that develops as a result of persistent venous obstruction and incompetent (or subcompetent) venous valves. Current treatments for venous outflow obstruction include anticoagulation, thrombolysis, balloon angioplasty and stenting.
Disclosed herein in accordance with various embodiments are stents that include pluralities of main struts and connector struts. For example, the inventors have designed the struts with structure, including areas of expanded or reduced width or thickness, to account for venous applications. As another example, the inventors have recognized that venous applications benefit from configurations that improve flexibility (due to the greater elasticity of venous applications) while maintaining enough stiffness to resist pressure on the venous structure in selected areas (such as for the May-Thurner syndrome). To that end, explored herein are particular structural characteristics—often expressed as ratios or ranges between different measurements—that the inventors have determined are particularly advantageous for (although not limited to) venous applications.
The dimensions and orientation of these struts are designed to provide flexibility and radial stiffness in combination with substantially reduced or, for practical purposes in venous applications, “zero” foreshortening that is particularly advantageous for use in venous applications. Such advantages are provided by use of oblique (or helically) oriented stent struts with opposingly oriented oblique connectors that form strips or strip fragments. Those strips or strip fragments (or portions) are then interconnected with flexible connectors that further mediate shortening.
Notably the stents herein are not necessarily limited to venous applications unless specifically required by the claims. The disclosed stents could be employed in arterial and biliary applications, for example. But, are particularly suited for the demands of relatively soft structures defining lumens that are subject to much greater bending, twisting, stretching and other contortions and loads than are general atrial lumens.
It should be noted that terms such as “perpendicular”, “oblique”, “thickness”, “length”, “width”, “adjacent”, “middle”, and other dimensional and geometric terms should not be regarded as strict or perfect in their application. Instead, geometric and other dimensional reference terms should be interpreted based on their correspondence to accepted manufacturing tolerances and functional needs of the stent on which they are employed. For example, the terms “perpendicular” and “straight” should be appreciated as affording a reasonable amount of angular variation due to manufacturing imperfections or the actual intentional curves cut or formed in the stent design. Also, any thickness, width or other dimension should be assessed based on tolerances and functional needs of the design rather than idealized measurements.
In the illustrations of
As shown in
Structural components of the stent 10 are formed from materials that facilitate reduced foreshortening while providing radial stiffness and flexibility. The main struts 14, first connector structs 16, and/or second connector struts 18, may be, for example formed from nitinol, spring steel, stainless steel, or durable polymer.
When the stent 10 is in a compressed state, for example when in a catheter for delivery, the main struts 14 align nearly in parallel with the centerline of the stent, e.g., nearly parallel to the long axis 11. When the stent 10 is deployed and expands into an uncompressed state, the angular orientation of the main struts 14 increases, such that the main struts 14 are each more obliquely oriented to the long axis 11. In an exemplary embodiment, the angle θ of orientation of the main struts 14 when the stent 10 is expanded in the unconstrained state is between 10 and 50 degrees from the long axis 11, which can be between 5 and 40 degrees when deployed into the patient's lumen. In some embodiments, the range of strut angles is between 15 and 30 degrees from the long axis in the unconstrainted state, which can be between 10 and 25 degrees when deployed into the lumen. In some embodiments, the change in angular orientation corresponds to rotation of the main struts 14 relative to the first connecting struts 16 when expanding from a compressed or otherwise constrained state.
As shown, each main strut 14 of each strip 12 has an oblique orientation relative to the long axis 11 of the stent 10 that is the same oblique orientation of the other main struts 14. It should be appreciated that the angle of orientation of one or more main struts may be different than that of others, either within the same strip or different strips of the stent, in order to provide desired expansion or compression performance of the stent. The second connector struts 18 are also oriented obliquely to the long axis of the stent 10, but at an angular orientation that is generally opposite the oblique orientation of the main struts 14. The second connector struts 18 having an opposite angle, with respect to the long axis of the stent 10, facilitates the angular change in the main struts 14 to increase the length of the second connector struts 18, thus minimizing the foreshortening of the entire stent.
In the exemplary embodiment of the stent 10 shown in
The main struts 14 are wider and longer than the first connector struts 16. In an exemplary embodiment, the main struts 14 are each at least twice as wide as the first connector struts 16. For example, the main struts may each be 0.03 inches wide, whereas the first connector struts may be 0.01 inches wide. The width of a strut as described herein is generally perpendicular to the strut radial direction. The length of a strut as described herein is generally the distance along the longitudinal axis of the strut between its opposite ends. The length of the first connector struts 16 can be 30%, 50%, or 70% of the length of the main struts 14. As can be particularly seen in the perspective view of
Each second connector strut 18 connects a main strut 14 of one strip 12 to a main strut 14 of the adjacent strip 12 by extending between the main struts 14. In particular, the second connector struts 18 connect from a location at approximately the middle of one main strut 14 to a location of an adjacent main strut 14 that is more proximate to an end of that adjacent main strut. This offset facilitates nesting together of adjacent portions formed by the main struts and first connector struts when the stent is compressed or under bending.
In the exemplary embodiment shown in
The strip 22 as shown in the laid-flat view of
As shown in further detail in the enlarged side view of
Structural components of the stent 20 are formed from materials that facilitate reduced foreshortening while providing radial stiffness and flexibility. The main struts 24, first connector structs 26, and/or second connector struts 28, may be, for example formed from nitinol, spring steel, stainless steel, or durable polymer.
As can be seen in detail in the perspective view of
The main struts 24 are wider and longer than the first connector struts 26. In an exemplary embodiment, the main struts 24 are each at least twice as wide as the first connector struts 26. For example, the main struts 24 may each be 0.03 inches wide, whereas the first connector struts 28 may be 0.01 inches wide. The length of the first connector struts 26 can be 30%, 50%, or 70% of the length of the main struts 24.
When the stent 20 is in a compressed state, for example when in a catheter for delivery, the main struts 24 align nearly in parallel with the centerline of the stent, more parallel to the long axis 21. When the stent 20 is deployed and expands into an uncompressed state, the angular orientation of the main struts 24 increases, such that the main struts 24 each become more obliquely oriented to the long axis 21. In an exemplary embodiment, the angle θ of orientation of the main struts 24 is between 10 and 50 degrees from the long axis 21 of the stent 20 when the stent 20 is in the expanded state.
In the embodiment shown, each main strut 24 of each strip 22 has an angle θ of orientation relative to the long axis 21 of the stent 20 that is the same as that of the other main struts 24. It should be appreciated that the angle of orientation of one or more main struts may be different than that of others, either within the same strip or different strips of the stent, in order to provide desired expansion or compression performance of the stent. The second connector struts 28 are also oriented obliquely to the long axis of the stent 20, but at an angular orientation that is generally opposite the oblique orientation of the main struts 24. The second connector struts having an opposite angle, with respect to the long axis of the stent, facilitates the angular change in the main struts to increase the length of the second connector struts, thus minimizing the foreshortening of the entire stent.
To deploy an implantable stent according to embodiments described herein, the stent may be radially compressed/crimped to a smaller diameter for loading onto/into a delivery catheter. The stent may be crimped over a balloon on the inner core of the delivery system which may be later inflated to expand the coiled stent to the desired diameter. The engagement fingers are pre-configured at specific locations to allow discrete incremental expansion of the stent. In some embodiments, the stent can be expanded in 0.5 mm increments. In some embodiments, more than one stent may be joined together. For example, the ultimate length of the stent can be controlled by joining any desired number of individual adaptive diameter cells via flexible or rigid bridge members.
Implantable stents such as those described above may advantageously provide an adaptive diameter and/or flexibility to conform the dynamic movement of peripheral veins in leg/pelvis thereby facilitating treatment of both iliac vein compression syndrome and ilio-femoral venous outflow obstructions.
It may be desirable to have a stent that will conform to the existing path of a vein instead of a straightening out of the vessel by the stent. It may also be desirable to have a high radial stiffness of the stent to resist collapse of the stent under crushing load and to maximize the resultant diameter of the treated vessel at the location of the stent deployment. With most stent constructions there is a direct relationship between radial stiffness and axial stiffness.
Common commercially available balloon expandable stents experience a dramatic change in length as a balloon is used to expand the stent within the vessel. Common commercially available self-expanding stents experience a change in length less dramatic, but still substantial, which increases with increasing stent length. Change in length between the configuration within the delivery system and when deployed in the vessel causes difficulty in placing/landing the stent precisely at the target location. When the stent is deployed in its crimped configuration and expanded, the shortening in length causes the stent target deployment location to have to offset from the target dwell location. The magnitude of this effect is not controllable or easily anticipated as it is dependent on the luminal cross-section along the length of the target dwell location (which is frequently and unexpectedly influenced by residual stenosis, irregular shape due to external objects, and/or forces, etc.). For target lesions leading up to the junction of the left and right iliac into the IVC, this causes difficulty in placing the stent to dwell completely within the iliac along its total length up to the junction to the inferior vena cava without crossing into the inferior vena cava.
In some embodiments a venous stent with high radial force, no impactful foreshortening along multiple lengths, and high flexibility/vessel conformity is provided. Minimization of foreshortening allows the stent advantageously accurate and predictable deployment. And, high flexibility maximizes the fatigue life of the stent under bending. Of course, it will be understood that the stent may find applications in the arterial system as well.
Embodiments disclosed herein can be used for both balloon expandable and self-expanding stent designs. The stent designs can be used for all stent interventions, including coronary, peripheral, carotid, neuro, biliary and, especially, venous applications. Additionally, this could be beneficial for stent grafts, percutaneous valves, etc.
Currently available implants are typically loaded and retained onto a delivery system in a crimped configuration and then navigated and deployed in the desired anatomical location where they expand to the implanted configuration. The final implanted configuration can be achieved through mechanical expansion/actuation (e.g., balloon-expandable) or self-expansion (e.g., Nitinol). Self-expanding implants are manufactured from super elastic or shape memory alloy materials. Accurate and precise deployment of a self-expanding implant can be challenging due to a number of inherent design attributes associated with self-expanding implants. The implant may jump/advance from the distal end of the delivery system during deployment due to the stored elastic energy of the material. Additionally, the implant may foreshorten during deployment due to the change in the implant diameter from the crimped configuration to the expanded configuration. Finally, physiological and anatomical configurations, such a placement at or near bifurcations of body lumens, can affect accurate placement of implants. Once the implant is placed within the body lumen there is potential for uneven expansion or lack of circumferential implant apposition to the body lumen which can result in movement, migration or in certain severe cases implant embolization.
In some embodiments, a self-expanding implant designed with sufficient radial force to resist constant compression of the body lumen while providing optimal fatigue resistance, accurate placement, and in-vivo anchoring to prevent is provided. Additionally, various methods for deployment and implantation for treating iliac vein compression syndrome and venous insufficiency disease are provided.
In some embodiments, the implant comprises a purposely designed stent intended to focally treat iliac vein compression (May-Thurner Syndrome). The implant may be relatively short in length (˜40 mm) and may be manufactured from self-expending Nitinol with integrated anchor features to aid in accurate placement and to mitigate migration following implantation. The implant and delivery system are designed for precise deployment and placement at the bifurcation of the inferior vena cava into the right and left common iliac veins.
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
Features described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including the accompanying claims, abstract, and drawings) and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.
Similarly, this method of disclosure, is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.
While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. It will be apparent to persons skilled in the relevant art that various changes in form and detail can be made therein without departing from the spirit and scope of the present invention. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
This application is a continuation of U.S. patent application Ser. No. 15/916,843, filed Mar. 9, 2018, now U.S. Pat. No. 10,500,078, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
5104404 | Wolff | Apr 1992 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5836966 | St. Germain | Nov 1998 | A |
5843120 | Israel et al. | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5868780 | Lashinski et al. | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5911754 | Kanesaka et al. | Jun 1999 | A |
5922005 | Richter et al. | Jul 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5964798 | Imran | Oct 1999 | A |
5972018 | Israel et al. | Oct 1999 | A |
6027526 | Limon et al. | Feb 2000 | A |
6033433 | Ehr et al. | Mar 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6059811 | Pinchasik et al. | May 2000 | A |
6068656 | Von Oepen | May 2000 | A |
6083259 | Frantzen | Jul 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6113627 | Jang | Sep 2000 | A |
6123721 | Jang | Sep 2000 | A |
6146403 | St. Germain | Nov 2000 | A |
6156052 | Richter | Dec 2000 | A |
6179868 | Burpee et al. | Jan 2001 | B1 |
6183507 | Lashinski et al. | Feb 2001 | B1 |
6190403 | Fischell et al. | Feb 2001 | B1 |
6200334 | Jang | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6235053 | Jang | May 2001 | B1 |
6241762 | Shanley | Jun 2001 | B1 |
6261319 | Kveen et al. | Jul 2001 | B1 |
6287336 | Globerman et al. | Sep 2001 | B1 |
6299635 | Frantzen | Oct 2001 | B1 |
6309414 | Rolando et al. | Oct 2001 | B1 |
6325821 | Gaschino et al. | Dec 2001 | B1 |
6325825 | Kula et al. | Dec 2001 | B1 |
6402777 | Gioberman et al. | Jun 2002 | B1 |
6428570 | Globerman | Aug 2002 | B1 |
6443982 | Israel et al. | Sep 2002 | B1 |
6451049 | Vallana et al. | Sep 2002 | B2 |
6461380 | Cox | Oct 2002 | B1 |
6461381 | Israel et al. | Oct 2002 | B2 |
6464722 | Israel et al. | Oct 2002 | B2 |
6475236 | Roubin | Nov 2002 | B1 |
6478816 | Kveen et al. | Nov 2002 | B1 |
6485508 | McGuinness | Nov 2002 | B1 |
6485509 | Killion et al. | Dec 2002 | B2 |
6497723 | Starck et al. | Dec 2002 | B1 |
6540775 | Fischell et al. | Apr 2003 | B1 |
6610086 | Kock et al. | Aug 2003 | B1 |
6635084 | Israel et al. | Oct 2003 | B2 |
6638300 | Frantzen | Oct 2003 | B1 |
6641609 | Globerman | Nov 2003 | B2 |
6660019 | Richter et al. | Dec 2003 | B1 |
6679911 | Burgermeister | Jan 2004 | B2 |
6682554 | Von Oepen et al. | Jan 2004 | B2 |
6692522 | Richter | Feb 2004 | B1 |
6699281 | Vallana et al. | Mar 2004 | B2 |
6706061 | Fischell et al. | Mar 2004 | B1 |
6709453 | Pinchasik et al. | Mar 2004 | B2 |
6730116 | Wolinsky et al. | May 2004 | B1 |
6746479 | Her et al. | Jun 2004 | B2 |
6761731 | Majercak | Jul 2004 | B2 |
6764506 | Roubin et al. | Jul 2004 | B2 |
6786922 | Schaeffer | Sep 2004 | B2 |
6790227 | Burgermeister | Sep 2004 | B2 |
6818015 | Hankh et al. | Nov 2004 | B2 |
6923829 | Boyle et al. | Aug 2005 | B2 |
6939373 | Gomez et al. | Sep 2005 | B2 |
6945993 | Kveen et al. | Sep 2005 | B2 |
7004968 | Lootz et al. | Feb 2006 | B2 |
7029493 | Majercak et al. | Apr 2006 | B2 |
7037330 | Rivelli, Jr. et al. | May 2006 | B1 |
7060088 | Fischell et al. | Jun 2006 | B1 |
7060090 | Thornton | Jun 2006 | B2 |
7070614 | Neuss et al. | Jul 2006 | B1 |
7131993 | Gregorich | Nov 2006 | B2 |
7141062 | Pinchasik et al. | Nov 2006 | B1 |
7273494 | Rolando et al. | Sep 2007 | B2 |
7316710 | Cheng et al. | Jan 2008 | B1 |
7326243 | Kveen et al. | Feb 2008 | B2 |
7344563 | Vallana et al. | Mar 2008 | B2 |
7357813 | Burgermeister | Apr 2008 | B2 |
7402169 | Killion | Jul 2008 | B2 |
7485130 | St. Germain | Feb 2009 | B2 |
7527644 | Mangiardi et al. | May 2009 | B2 |
7621947 | Richter et al. | Nov 2009 | B2 |
7648526 | Sano et al. | Jan 2010 | B2 |
7686843 | Moore | Mar 2010 | B2 |
7731746 | Kveen et al. | Jun 2010 | B2 |
7806918 | Nissl et al. | Oct 2010 | B2 |
7862607 | McDermott et al. | Jan 2011 | B2 |
7896912 | Shanley | Mar 2011 | B2 |
8012196 | Smith et al. | Sep 2011 | B2 |
8016874 | Casey | Sep 2011 | B2 |
8128679 | Casey | Mar 2012 | B2 |
8206427 | Ryan et al. | Jun 2012 | B1 |
8211163 | Dakin et al. | Jul 2012 | B2 |
8221489 | Issenmann et al. | Jul 2012 | B2 |
8257424 | Orlowski | Sep 2012 | B2 |
8267991 | De Scheerder et al. | Sep 2012 | B2 |
8317854 | Ryan et al. | Nov 2012 | B1 |
8317859 | Snow et al. | Nov 2012 | B2 |
8337544 | Osman et al. | Dec 2012 | B2 |
8348990 | Boyle et al. | Jan 2013 | B2 |
8470021 | Magnuson et al. | Jun 2013 | B2 |
8524132 | Von Oepen et al. | Sep 2013 | B2 |
8562665 | Jang | Oct 2013 | B2 |
8647379 | McDermott et al. | Feb 2014 | B2 |
8652196 | Nissl | Feb 2014 | B2 |
8668731 | Kveen et al. | Mar 2014 | B2 |
8888837 | Obradović et al. | Nov 2014 | B2 |
8974514 | Anukhin et al. | Mar 2015 | B2 |
9066825 | Chanduszko | Jun 2015 | B2 |
9320627 | Casey | Apr 2016 | B2 |
9375810 | Mangiardi | Jun 2016 | B2 |
9408727 | Ainsworth et al. | Aug 2016 | B2 |
9445926 | Jang | Sep 2016 | B2 |
9498360 | Layman et al. | Nov 2016 | B2 |
9554927 | Bales, Jr. et al. | Jan 2017 | B2 |
9561123 | Bales, Jr. et al. | Feb 2017 | B2 |
9622850 | Bebb | Apr 2017 | B2 |
9649211 | Bonsignore et al. | May 2017 | B2 |
9655998 | Gemborys | May 2017 | B2 |
9668895 | Dreher | Jun 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9693860 | Sandstrom et al. | Jul 2017 | B2 |
9700448 | Snow et al. | Jul 2017 | B2 |
9707110 | McDermott et al. | Jul 2017 | B2 |
9724220 | Rasmussen | Aug 2017 | B2 |
9770348 | Wack | Sep 2017 | B2 |
9795496 | Armstrong et al. | Oct 2017 | B2 |
9839538 | Grewe et al. | Dec 2017 | B2 |
9839540 | Armstrong et al. | Dec 2017 | B2 |
10076431 | Sirhan et al. | Sep 2018 | B2 |
20010014822 | Milo | Aug 2001 | A1 |
20010047200 | White et al. | Nov 2001 | A1 |
20020013616 | Carter et al. | Jan 2002 | A1 |
20020042648 | Schaldach et al. | Apr 2002 | A1 |
20020058990 | Jang | May 2002 | A1 |
20020120327 | Cox et al. | Aug 2002 | A1 |
20030009214 | Shanley | Jan 2003 | A1 |
20030014102 | Hong et al. | Jan 2003 | A1 |
20030055485 | Lee et al. | Mar 2003 | A1 |
20030100941 | Fischell et al. | May 2003 | A1 |
20030105513 | Moriuchi et al. | Jun 2003 | A1 |
20030105517 | White et al. | Jun 2003 | A1 |
20040054398 | Cully et al. | Mar 2004 | A1 |
20040054400 | Granada | Mar 2004 | A1 |
20040102835 | Israel et al. | May 2004 | A1 |
20040133265 | Duffy | Jul 2004 | A1 |
20040254627 | Thompson et al. | Dec 2004 | A1 |
20040267350 | Roubin et al. | Dec 2004 | A1 |
20050004657 | Burgermeister | Jan 2005 | A1 |
20050021130 | Kveen et al. | Jan 2005 | A1 |
20050060024 | Lee et al. | Mar 2005 | A1 |
20050080479 | Feng et al. | Apr 2005 | A1 |
20060025852 | Armstrong et al. | Feb 2006 | A1 |
20060129227 | Hengelmolen | Jun 2006 | A1 |
20060173531 | Richter | Jun 2006 | A1 |
20070005126 | Tisohler | Jan 2007 | A1 |
20070010869 | Sano | Jan 2007 | A1 |
20070213806 | Roubin et al. | Sep 2007 | A1 |
20070213807 | Roubin et al. | Sep 2007 | A1 |
20070219613 | Kao et al. | Sep 2007 | A1 |
20070239251 | Prabhu et al. | Oct 2007 | A1 |
20080009938 | Huang et al. | Jan 2008 | A1 |
20080051878 | Cheng et al. | Feb 2008 | A1 |
20080140181 | Reynolds et al. | Jun 2008 | A1 |
20080177373 | Huang | Jul 2008 | A1 |
20080288048 | Rolando et al. | Nov 2008 | A1 |
20080300674 | Jang | Dec 2008 | A1 |
20090018641 | Binkert | Jan 2009 | A1 |
20090062899 | Dang et al. | Mar 2009 | A1 |
20100004736 | Rolando et al. | Jan 2010 | A1 |
20100222864 | Rivelli, Jr. et al. | Sep 2010 | A1 |
20100241216 | Rolando et al. | Sep 2010 | A1 |
20110125251 | Cottone et al. | Feb 2011 | A1 |
20110106237 | Bonsignore et al. | May 2011 | A1 |
20110230957 | Bonsignore et al. | Sep 2011 | A1 |
20120043703 | Von Oepen et al. | Feb 2012 | A1 |
20120046729 | Von Oepen et al. | Feb 2012 | A1 |
20120046730 | Von Oepen et al. | Feb 2012 | A1 |
20120046731 | Von Oepen et al. | Feb 2012 | A1 |
20120046733 | Von Oepen et al. | Feb 2012 | A1 |
20120046739 | Von Oepen et al. | Feb 2012 | A1 |
20120143312 | Brown | Jun 2012 | A1 |
20120277844 | Wu | Nov 2012 | A1 |
20120310327 | McHugo | Dec 2012 | A1 |
20130178928 | Vyas et al. | Jul 2013 | A1 |
20130218254 | Cattaneo | Aug 2013 | A1 |
20130304192 | Chanduszko | Nov 2013 | A1 |
20130325141 | Gill et al. | Dec 2013 | A1 |
20140081371 | Poehlmann | Mar 2014 | A1 |
20140277365 | Gillespie | Sep 2014 | A1 |
20140277378 | Lane et al. | Sep 2014 | A1 |
20150105852 | Noffke et al. | Apr 2015 | A1 |
20150209167 | Mangiardi | Jul 2015 | A1 |
20150250580 | Besselink | Sep 2015 | A1 |
20160235562 | Casey | Aug 2016 | A1 |
20160250052 | Kaspar | Sep 2016 | A1 |
20160287418 | Cheng et al. | Oct 2016 | A1 |
20170035548 | Bebb et al. | Feb 2017 | A1 |
20170071768 | Krieger et al. | Mar 2017 | A1 |
20170086994 | Bales et al. | Mar 2017 | A1 |
20170100267 | Bales et al. | Apr 2017 | A1 |
20170224878 | Gemborys | Aug 2017 | A1 |
20170265998 | Sandstrom et al. | Sep 2017 | A1 |
20170312104 | McDermott et al. | Nov 2017 | A1 |
20170312105 | McDermott et al. | Nov 2017 | A1 |
20170340464 | Kovach et al. | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
1088528 | Apr 2001 | EP |
3043754 | Jul 2016 | EP |
3123983 | Feb 2017 | EP |
2006026779 | Mar 2006 | WO |
2009012417 | Jan 2009 | WO |
2015038790 | Mar 2015 | WO |
Entry |
---|
International Search Report and Written Opinion for Application No. PCT/USD2019/021322 dated May 21, 2019. |
Number | Date | Country | |
---|---|---|---|
20200069448 A1 | Mar 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15916843 | Mar 2018 | US |
Child | 16671859 | US |